Style | Citing Format |
---|---|
MLA | Moghadam ES, et al.. "Piperazine-Based Semicarbazone Derivatives As Potent Urease Inhibitors: Design, Synthesis, and Bioactivity Screening." Letters in Drug Design and Discovery, vol. 19, no. 12, 2022, pp. 1111-1120. |
APA | Moghadam ES, Alsadi AM, Talebi M, Amanlou M, Shongwe M, Amini M, Abdeljalil R (2022). Piperazine-Based Semicarbazone Derivatives As Potent Urease Inhibitors: Design, Synthesis, and Bioactivity Screening. Letters in Drug Design and Discovery, 19(12), 1111-1120. |
Chicago | Moghadam ES, Alsadi AM, Talebi M, Amanlou M, Shongwe M, Amini M, Abdeljalil R. "Piperazine-Based Semicarbazone Derivatives As Potent Urease Inhibitors: Design, Synthesis, and Bioactivity Screening." Letters in Drug Design and Discovery 19, no. 12 (2022): 1111-1120. |
Harvard | Moghadam ES et al. (2022) 'Piperazine-Based Semicarbazone Derivatives As Potent Urease Inhibitors: Design, Synthesis, and Bioactivity Screening', Letters in Drug Design and Discovery, 19(12), pp. 1111-1120. |
Vancouver | Moghadam ES, Alsadi AM, Talebi M, Amanlou M, Shongwe M, Amini M, et al.. Piperazine-Based Semicarbazone Derivatives As Potent Urease Inhibitors: Design, Synthesis, and Bioactivity Screening. Letters in Drug Design and Discovery. 2022;19(12):1111-1120. |
BibTex | @article{ author = {Moghadam ES and Alsadi AM and Talebi M and Amanlou M and Shongwe M and Amini M and Abdeljalil R}, title = {Piperazine-Based Semicarbazone Derivatives As Potent Urease Inhibitors: Design, Synthesis, and Bioactivity Screening}, journal = {Letters in Drug Design and Discovery}, volume = {19}, number = {12}, pages = {1111-1120}, year = {2022} } |
RIS | TY - JOUR AU - Moghadam ES AU - Alsadi AM AU - Talebi M AU - Amanlou M AU - Shongwe M AU - Amini M AU - Abdeljalil R TI - Piperazine-Based Semicarbazone Derivatives As Potent Urease Inhibitors: Design, Synthesis, and Bioactivity Screening JO - Letters in Drug Design and Discovery VL - 19 IS - 12 SP - 1111 EP - 1120 PY - 2022 ER - |